CTLA-4-expressing CD4 T cells are critical contributors to SIV viral persistence
|
|
- Brendan Cannon
- 5 years ago
- Views:
Transcription
1 IAS 2015 Towards an HIV Cure symposium Vancouver CTLA-4-expressing CD4 T cells are critical contributors to SIV viral persistence Colleen McGary Paiardini lab Emory University
2 HIV reservoir prevents eradication of HIV infection Treatment interruption Deeks S, et al. Nat Rev Imm 2012 Viral rebound ART is unable to eliminate virally infected cells (Finzi D, et al. 1997; Wong JK, et al. 1997; Strain MC, et al. 2005) Viral reservoir is established early during infection (Finzi D, et al. 1997; Chun T.W., et al. 1998; Whitney JB, et al. 2014) Resting memory CD4+ T cells are the best characterized viral reservoir (Siliciano JD, et al. 2003) Central and transitional memory CD4 (Chomont N, et al. 2009; Soriano-Sarabia N, et al. 2014) Stem cell memory CD4 (Buzon MJ, et al. 2014; Jaafoura S., et al. 2014) Frequency of latently infected resting CD4+ T cells is 1 in 10 6 (Chun T.W., et al. 1997)
3 Understanding the immunophenotype and anatomic location of latently infected cells Study Objective: to determine the relationship between the expression of co-inhibitory receptors and the level of latent viral infection
4 Co-inhibitory receptors and HIV/SIV Negatively regulate T cell activation and proliferation Several co-inhibitory receptors are upregulated on CD4 and CD8 T cells following HIV-1 infection PD-1, CTLA-4, TIM-3, LAG-3, CD160 Upregulation associated with T cell dysfunction and exhaustion (Day CL, et al. Nature 2006; Trautmann L. et al, Nat Med, 2006; Kaufmann DE, et al. Nat Imm, 2007; Jones RB, et al. J Ex Med, 2008; Petrovas C, et al. J Ex Med, 2006) T cell dysfunction unable to be restored by ART (Betts MR, et al. Blood 2006) PD-1+ cells are significantly enriched in HIV DNA in ART-treated HIV+ subjects (Chomont N, et al. Nat Med 2009) Larsson M, et al. Retrovirology 2013 CTLA-4+ CD4+ T cells are highly permissive to HIV in vitro and are preferentially infected in ART-naïve HIV+ individuals (El-Far M, et al. J Gen Virol. 2015)
5 Advantages to using NHP models in studies of HIV reservoir/cure 1. Ability to determine and control for clinical parameters that are virtually impossible to control in humans (Identity, dose, and route of virus challenge, time of infection, duration of ART, etc). 2. Ability to perform longitudinal collections in multiple anatomic locations (PB, LN, RB, BM) and elective necropsy: comprehensive cellular and anatomic characterization of virus reservoirs. 3. cart is able to achieve effective suppression of viral replication. (Shytaj IL, Norelli S, et al. PLoS Path. 2012; Del Prete GQ, et al. Antimicrob Agents Chemother. 2014; Del Prete GQ, et al. AIDS Res Hum Retroviruses 2015) 4. Ability to test novel and risky interventions for HIV eradication (i.e. combination therapy, cell depletion, stem cell-based interventions, etc.).
6 Study Design 10 RMs (4-10 yr old); 3 A01+, all B08- &B17- SIVmac TCID50, i.v. Initiate ART Maraviroc 5-drug ART initiated (7) (PMPA, FTC, raltegravir, darunavir/ritonavir) Necropsy Month Day Blood/RB collected at time points indicated; LN collected D14, 52, 90, drug ART regimen: Tenofovir/PMPA NRTI mg/kg/d Emtricitabine/FTC NRTI mg/kg/d Raltegravir Integrase inhibitor mg/bid Darunavir Protease inhibitor mg/bid Ritonavir (boost) PI (P-gp inhibitor) 50 mg/bid Maraviroc [7 RMs] CCR5 antagonist mg/bid Sorts performed for cell-associated SIV DNA/RNA from CD4+ co-inhibitory subsets: MidART (D200+): PBMCs, LN Necropsy (D270+): PBMCs, LN, Spleen, Gut mucosa
7 Five-drug ART regimen effectively suppressed viral replication in SIVmac251-infected RMs Average time to initial suppression: 151 days Limit of detection: 60 copies/ml
8 Enhanced co-inhibitory receptor staining after stimulation 3 hr PMA/Ionomycin stimulation: (surface staining) TIM-3 PD-1 CTLA-4
9 PD-1+CTLA-4+ CD4+ T cells comprise the majority of memory CD4+ T cells PBMCs SIV(-) Pre-ART Necrops y RB LN
10 Sorting Gating Strategy SIV+ RM LN ART-treated Stimulated 3 hr PMA + Iono Necropsy: 1 st sort: PD-1 (+) and (-) PD-1(-) 2 nd sort: CTLA-4, TIM3 combinations PD-1(+) MidART: 4 population sort Necropsy: 8 population sort
11 SIV DNA enrichment is only found in the lymph node after short duration of virus suppression MidART PBMCs LN MidART: 1 month undetectable plasma viremia (80±40 d)
12 Necropsy CTLA-4-expressing memory CD4 T cells harbor high levels of SIV DNA PBMCs LN Spleen Mucosa Necropsy: 3 months post undetectable plasma viremia (125±77d) TIM3+ cells represented by open symbols
13 Levels of CA-SIV DNA in blood decrease faster in memory CD4 T cells lacking co-inhibitory expression PBMCs MidART: 1 month undetectable plasma viremia (80±40 d) Necropsy: 3 months post undetectable plasma viremia (125±77d)
14 PD-1 and CTLA-4-expressing CD4 T cells contribute significantly more to the SIV DNA pool PBMCs LN Spleen Mucosa Contributions to SIV DNA pool at necropsy:
15 PD-1 and CTLA-4-expressing CD4 T cells contribute significantly more to the SIV DNA pool Rationale to test efficacy of PD-1/CTLA-4 dual blockade in setting of ART Targeting between 76-88% of infected CD4+ T cells Reinvigorate dysfunctional antiviral CD8+ T cells
16 CTLA-4 Blockade in an HIV+ Patient Fiona Wightman, Ajantha Solomon, Sanjeev S. Kumar, Nicolas Urriola, Kerri Gallagher, Bonnie Hiener, Sarah Palmer, Catriona Mcneil, Roger Garsia, and Sharon R. Lewin Ipilimumab produced greater changes in CA-US HIV RNA than what has been previously reported for HDAC inhibitors (vorinostat, panobinostat) or disulfiram CTLA-4 blockade resulted in 19.6-fold increase in cell-associated unspliced HIV RNA
17 Conclusions Five-drug ART regimen effectively suppresses plasma viremia Undetectable plasma viremia (<60 copies/ml) in 9 of 10 RMs Frequencies of PD-1+CTLA-4+ CD4+ memory T cells increase during SIV infection, despite ART suppression of plasma viremia CTLA-4(+) CD4+ T cells are significantly enriched in SIV DNA Enrichment persists over time Enrichment found across multiple tissue compartments: In PBMCs, LN, spleen, and mucosa at necropsy In LN compared to DP (double positive) cells at midart Limited to cell-associated DNA and RNA quantification Pursuing in situ hybridization confirmation and SGA sequencing for further characterization PD-1 and CTLA-4-expressing cells are major contributors to the SIV DNA pool within memory CD4+ T cells Rationale to target these two pathways in combination with ART
18 Future Dual Blockade Study To determine the efficacy of blocking the PD-1 and CTLA-4 pathways in targeting the persistent viral reservoir in ART-treated, SIV-infected RMs Group 1: SIVmac239 (i.v.) actla-4/pd-1 cart actla-4/pd-1 3-drug ART (PMPA, FTC, DTG) actla-4/pd-1 cart Interruption 4 months Necropsy Week Group 2: apd-1 apd-1 apd-1 Group 1: receive actla-4/pd-1 Abs, s.c. (12 RMs) Group 2: receive anti-pd-1 Ab, s.c. (8 RMs) Group 3: receive no Ab, ART alone (8 RMs)
19 Acknowledgements Paiardini lab Sara Paganini Luca Micci Emily Ryan Justin Harper Yerkes Flow Cytometry Core Barbara Cervasi John Altman Kiran Gill Ragon Institute Mathias Lichterfeld Maria Buzon Sean Harrington Xu Yu CFAR Virology Core Thomas Vanderford Benton Lawson Melon Nega NCI Jeff Lifson Michael Piatak Jake Estes Emory- YNPRC Guido Silvestri Ann Chahroudi Diane Carnathan Ankita Chowdhury Jakob Habib Elizabeth Strobert Stephanie Ehnert Chris Souder Sherrie Jean NIH/NIAID Jason Brenchley Case Western Rafick Sekaly Drugs Daria Hazuda (Merck) Romas Geleziunas (Gilead) Guenter Kraus (Janssen) Supported by NIH R21/R33 AI104278, RO1 AI PHS RR000165/OD011132
20
21
22
23
Combined IL-21 and IFNα treatment limits inflammation and delay viral rebound in ART-treated, SIV-infected macaques
Combined and IFNα treatment limits inflammation and delay viral rebound in ART-treated, SIV-infected macaques Mirko Paiardini Associate Professor, Emory University School of Medicine Yerkes National Primate
More informationInterleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaques
Interleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaques Luca Micci, Emory University Emily S. Ryan, Emory University Rémi Fromentin, Université de Montréal Steven
More informationT Memory Stem Cells: A Long-term Reservoir for HIV-1
Towards an HIV Cure Pre-Conference Symposium 20 & 21 July 2012 T Memory Stem Cells: A Long-term Reservoir for HIV-1 Maria J Buzon, PhD Ragon Institute of MGH, MIT and Harvard, Massachussetts General Hospital,
More informationNovel Approaches for the Assessment of the In Vivo Residual Virus Pool and Viral Eradication Strategies in SIV-infected Rhesus Macaques
Towards an HIV Cure Pre-Conference Symposium 20 & 21 July 2012 Novel Approaches for the Assessment of the In Vivo Residual Virus Pool and Viral Eradication Strategies in SIV-infected Rhesus Macaques Gregory
More informationViral Reservoirs and anti-latency interventions in nonhuman primate models of SIV/SHIV infection
Viral Reservoirs and anti-latency interventions in nonhuman primate models of SIV/SHIV infection Koen Van Rompay California National Primate Research Center University of California Davis Outline Introduction
More informationProfessor Jonathan Weber
HIV/AIDS at 30: Back to the Future BHIVA / Wellcome Trust Multidisciplinary Event to mark World AIDS Day 2011 British HIV Association (BHIVA) 2011 HIV/AIDS at 30: Back to the Future BHIVA / Wellcome Trust
More informationCan HIV be cured? (how about long term Drug free remission?)
Can HIV be cured? (how about long term Drug free remission?) Shirin Heidari International AIDS Society EC Think Tank meeting 27-28 October 2010 Luxemburg HAART can control HIV, cannot eradicate it Life
More informationWith over 20 drugs and several viable regimens, the mo6vated pa6ent with life- long access to therapy can control HIV indefinitely, elimina6ng the
Towards an HIV Cure Steven G. Deeks, MD Professor of Medicine in Residence HIV/AIDS Division University of California, San Francisco (UCSF) WorldMedSchool; July 22, 2013 1 With over 20 drugs and several
More informationHIV Cure Update. Christine Durand, MD 14 de abril de 2016, XIII Conferência Brasil Johns Hopkins University em HIV/AIDS
HIV Cure Update Christine Durand, MD 14 de abril de 2016, XIII Conferência Brasil Johns Hopkins University em HIV/AIDS Financial Disclosures Research grants paid to my institution: Gilead Sciences, Bristol
More informationThe potential role of PD-1/PD-L1 blockade in HIV Remission and Cure Strategies
The potential role of PD-1/PD-L1 blockade in HIV Remission and Cure Strategies Stephen Mason Director, Discovery Virology Bristol-Myers Squibb Community Cure Workshop 2015 Sunday, Feb 22, 2015 Seattle,
More informationTowards an HIV Cure. Steven G. Deeks Professor of Medicine University of California, San Francisco
Towards an HIV Cure Steven G. Deeks Professor of Medicine University of California, San Francisco Why are we now talking about a cure? Emerging recognition that HAART does not fully restore health and/or
More informationSupplementary Figure 1. Gating strategy and quantification of integrated HIV DNA in sorted CD4 + T-cell subsets.
Supplementary information HIV reservoir size and persistence are driven by T-cell survival and homeostatic proliferation. Chomont, N., M. El Far, P. Ancuta, L. Trautmann, F. A. Procopio, B. Yassine-Diab,
More informationInves&gación básica y curación del VIH-1
Inves&gación básica y curación del VIH-1 Javier Mar&nez-Picado 24 th Conference on Retroviruses and Opportunis6c Infec6ons UNIVERSITAT DE VIC Empezamos bien cart: How Early is Early Enough? Sáez-Cirion
More informationEstablishment and Targeting of the Viral Reservoir in Rhesus Monkeys
Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys Dan H. Barouch, M.D., Ph.D. Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center Ragon Institute of MGH, MIT,
More informationAnimal models in HIV cure research.
Animal models in HIV cure research. Luca Micci, Yerkes National Primate Research Center Mirko Paiardini, Emory University Colleen S. McGary, Yerkes National Primate Research Center Journal Title: Journal
More informationImpact of Vorinostat Treatment of Non- Hodgkin s Lymphoma on HIV-1 Latent Reservoir
Impact of Vorinostat Treatment of Non- Hodgkin s Lymphoma on HIV-1 Latent Reservoir Adam Capoferri, Juan Carlos Ramos, Daniel Xu, Daniel I.S. Rosenbloom, Janet D. Siliciano, Robert F. Siliciano, Ariela
More informationApproaching a Cure Daniel R. Kuritzkes, MD
Approaching a Cure Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker is a consultant and/or has received speaking honoraria
More informationInves)gación básica y curación del VIH- 1
Inves)gación básica y curación del VIH- 1 Javier Mar)nez- Picado (jmpicado@irsicaixa.es) 23 rd Conference on Retroviruses and Opportunis5c Infec5ons February 22-25, 2016 Boston, Massachuse8s UNIVERSITAT
More informationWorking Group#1: Trial Endpoints, Biomarkers & Definitions
Working Group#1: Trial Endpoints, Biomarkers & Definitions Forum HIV Cure Project: Focus on The Regulatory Pathway June 17, 2014 www.hivforum.org Comments from co-chairs john mellors and mike miller www.hivforum.org
More informationcure research HIV & AIDS
Glossary of terms HIV & AIDS cure research Antiretroviral Therapy (ART) ART involves the use of several (usually a cocktail of three or more) antiretroviral drugs to halt HIV replication. ART drugs may
More informationThe Impact of Immunoglobulin in Acute HIV Infection on the HIV Reservoir: A Pilot Randomized Controlled Trial
The Impact of Immunoglobulin in Acute HIV Infection on the HIV Reservoir: A Pilot Randomized Controlled Trial Olubanke Davies Guy s & St Thomas NHS Foundation Trust BACKGROUND Immediate ART during acute
More informationClinical HIV-1 eradication studies
Clinical HIV-1 eradication studies Mathias Lichterfeld, M. D., Ph. D. Massachusetts General Hospital Harvard Medical School No disclosures HIV-1 persistence despite HAART Blood Tissue HIV RNA (cps/ml)
More informationDual approach to HIV-1 cure: Activation of latency and restoration of exhausted virus-specific T cell function
Dual approach to HIV-1 cure: Activation of latency and restoration of exhausted virus-specific T cell function Stephen Mason Director, Discovery Virology Bristol-Myers Squibb Disclosure: Paid employee
More informationEradication of HIV infection Not in my lifetime? or Just around the Corner? Michael M. Lederman, MD
Eradication of HIV infection Not in my lifetime? or Just around the Corner? Michael M. Lederman, MD Conflicts of Interest The pending clinical trials discussed here are funded by grant awards from Gilead
More informationHIV Antibody Characterization for Reservoir and Eradication Studies. Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks
HIV Antibody Characterization for Reservoir and Eradication Studies Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks Blood Systems Research Institute University of California San Francisco, CA
More informationIAS 2016 Towards an HIV Cure Symposium Durban, South Africa.
Effect of vorinostat, hydroxychloroquine and maraviroc combination therapy on viremia following treatment interruption in individuals treated during acute HIV infection Eugène Kroon, Jintanat Ananworanich,
More informationCTLA-4 + PD-1 Memory CD4 + T Cells Critically Contribute to Viral Persistence in Antiretroviral Therapy-Suppressed, SIV-Infected Rhesus Macaques
Article CTLA-4 + PD-1 Memory CD4 + T Cells Critically Contribute to Viral Persistence in Antiretroviral Therapy-Suppressed, SIV-Infected Rhesus Macaques Graphical Abstract Authors Colleen S. McGary, Claire
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationHIV remission: viral suppression in the absence of ART. Sarah Fidler Brian Gazzard Lecture BHIVA 2016
HIV remission: viral suppression in the absence of ART Sarah Fidler Brian Gazzard Lecture BHIVA 2016 Disclosures: My institution receives funding for research from MSD, GSK, ViiV, Gilead Summary of talk
More informationHIV 101: Fundamentals of HIV Infection
HIV 101: Fundamentals of HIV Infection David H. Spach, MD Professor of Medicine University of Washington Seattle, Washington Learning Objectives After attending this presentation, learners will be able
More informationThe Role of B Cell Follicles in HIV Replication and Persistence
The Role of B Cell ollicles in HIV Replication and Persistence Elizabeth Connick, M.D. Professor of Medicine Chief, Division of Infectious Diseases University of Arizona July 17, 2016 IAS 2016 Towards
More information5/11/2017. HIV Cure Research Questions and a Few Answers
HIV Cure Research Questions and a Few Answers Steven G. Deeks, MD Professor of Medicine University of California San Francisco San Francisco, California FORMATTED: 04/13/17 Financial Relationships With
More informationRecent Insights into HIV Pathogenesis and Treatment: Towards a Cure
Recent Insights into HIV Pathogenesis and Treatment: Towards a Cure Deborah Persaud, M.D. Associate Professor Department of Pediatrics Division of Infectious Diseases Johns Hopkins University School of
More informationPROSPECTS FOR HIV CURE IN ADULTS. Nov 11 th 2013 John Frater
PROSPECTS FOR HIV CURE IN ADULTS FIS 2013 Nov 11 th 2013 John Frater April 29 th 2013; Telegraph online THE COMPONENTS OF A CURE. What is cure? Issues to consider: Post treatment control the benefit of
More informationClinical Development of ABX464, drug candidate for HIV Functional Cure. Chief Medical Officer ABIVAX
Clinical Development of ABX464, drug candidate for HIV Functional Cure Jean-Marc Steens, MD Chief Medical Officer ABIVAX 1 DECLARATION OF CONFLICT OF INTEREST GSK ABIVAX 2 ABX464: Mechanism of Action ABX464
More informationInnovative diagnostics for HIV, HBV and HCV
Innovative diagnostics for HIV, HBV and HCV Dan Otelea National Institute for Infectious Diseases Bucharest, Romania Disclaimer No conflicts of interest Innovative diagnostics for HIV, HBV and HCV - is
More informationTargeting latent HIV infection: on the road towards an HIV Cure
Towards an HIV Cure Pre-Conference Symposium 20 & 21 July 2012 Targeting latent HIV infection: on the road towards an HIV Cure David M. Margolis, MD Professor of Medicine Treatment Cure Prevention Prevention
More informationIntroduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School
Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.
More informationEXPLORING THE IMPACT OF SEX DISCREPANCIES IN HIV TREATMENT AND CURE
EXPLORING THE IMPACT OF SEX DISCREPANCIES IN HIV TREATMENT AND CURE CECILE DELILLE LAHIRI, M.D, M.SC ASSISTANT PROFESSOR DIVISION OF INFECTIOUS DISEASES MAY 18, 2016 OUTLINE Describe discrepancy between
More informationIAS 2015 Towards an HIV Cure symposium Vancouver. Distinct HIV Genetic Populations in Effector Memory T Cells after Prolonged Therapy
IAS 25 Towards an HIV Cure symposium Vancouver Distinct HIV Genetic Populations in Effector Memory T Cells after Prolonged Therapy Questions about long-lived HIV reservoirs Effective ART Memory CD4+ T
More informationEffect of 24 Week Intensification with a CCR5-Antagonist on the Decay of the HIV-1 Latent Reservoir
Effect of 24 Week Intensification with a CCR5-Antagonist on the Decay of the HIV-1 Latent Reservoir Laura Díaz 1, Carolina Gutiérrez 2, Carmen Page 2, Raquel Lorente 1, Beatriz Hernández-Novoa 2, Alejandro
More informationImpact of ART in Primary HIV infection on T cell immune exhaustion in Gut- associated lymphoid tissue: Implications for HIV persistence
Impact of ART in Primary HIV infection on T cell immune exhaustion in Gut- associated lymphoid tissue: Implications for HIV persistence THORNHILL J, MARTIN GE, HERRERA C, HOPKINS E, FIDLER S, FRATER J
More informationHow to best manage HIV patient?
How to best manage HIV patient? 1 2 Treatment Treatment Failure success HIV therapy = a long life therapy Why do we want to change a suppressive ART? Side effect Comorbidities Reduce drug burden How to
More informationTherapeutic strategies for immune reconstitution in acquired immunodeficiency syndrome
30 1, 1, 2, 3 1. ( ), 201508; 2., 200040; 3., 200032 : ( AIDS) ( HIV) 20 90,,,,,, AIDS, CD4 + T ( CTL), HIV, : ; ; Therapeutic strategies for immune reconstitution in acquired immunodeficiency syndrome
More informationHIV 101. Applications of Antiretroviral Therapy
HIV 101. Applications of Antiretroviral Therapy Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham,
More informationComplete Transcriptome Analysis of Latently Infected CD4 + T Cells
Towards an HIV Cure Pre-Conference Symposium 20 & 21 July 2012 Complete Transcriptome Analysis of Latently Infected CD4 + T Cells Fabio Romerio Institute of Human Virology University of Maryland School
More informationDr Anna Herasimtschuk
19 th Annual Conference of the British HIV Association (BHIVA) Dr Anna Herasimtschuk Imperial College London 16-19 April 213, Manchester Central Convention Complex Therapeutic immunisation in conjunction
More informationHIV cure research: current strategies and challenges. current strategies to eliminate latently infected cells 2/10/2015
Viral load // HIV cure research: current strategies and challenges Sharon R Lewin Director, Doherty Institute for Infection and Immunity, The University of Melbourne, Consultant physician, The Alfred,
More informationInhibition of HIV-1 Integration in Ex Vivo-Infected CD4 T Cells from Elite Controllers
JOURNAL OF VIROLOGY, Sept. 2011, p. 9646 9650 Vol. 85, No. 18 0022-538X/11/$12.00 doi:10.1128/jvi.05327-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Inhibition of HIV-1 Integration
More informationHacia la Curación del VIH
Jornadas 2012 Actualización en Atención Farmacéutica al Paciente Con Patologías Víricas Hacia la Curación del VIH Santiago Moreno Servicio de Enfermedades Infecciosas Hospital Ramón y Cajal Madrid HIV
More informationDr Jintanat Ananworanich
BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Dr Jintanat Ananworanich US Military HIV Research Program in Bethesda Maryland, USA 9-10 October 2014, Queen Elizabeth II Conference Centre,
More informationMHRP. Outline. Is HIV cure possible? HIV persistence. Cure Strategies. Ethical and social considerations. Short video on patients perspectives on cure
Outline Is HIV cure possible? Ø HIV persistence Cure Strategies Ethical and social considerations Short video on patients perspectives on cure A Case of Cure Off ART Treatment Mechanism Lesson The Berlin
More informationHIV Reservoirs in Developing Countries: Implication for HIV CURE Strategies
HIV Reservoirs in Developing Countries: Implication for HIV CURE Strategies 10 th INTEREST CONFERENCE 2016, 3-6 TH May 2016, Yaoundé, Cameroon Cissy Kityo 1 ; Thomas Schacker 2 ; Francis Ssali 1 ; Jeffrey
More informationHIV and Cancer Curative Approaches Cross-disciplinary research. Steven Deeks, MD Professor of Medicine University of California, San Francisco
HIV and Cancer Curative Approaches Cross-disciplinary research Steven Deeks, MD Professor of Medicine University of California, San Francisco Cancer immunotherapy is reshaping a fatal and progressive disease
More informationJournal of Infectious Diseases Advance Access published July 11, Effect of Antiretroviral Therapy on HIV Reservoirs in Elite Controllers
Journal of Infectious Diseases Advance Access published July 11, 2013 1 Effect of Antiretroviral Therapy on HIV Reservoirs in Elite Controllers Tae-Wook Chun 1,6, J. Shawn Justement 1, Danielle Murray
More informationOptimizing the treatment
PIs are the real world answer for: Optimizing the treatment Sergio Lo Caputo Malattie Infettive - Azienda Sanitaria Firenze Evolution of ARVs DARUNAVIR PI ETRAVIRINA NNRTI DOLUTEGRAVIR INI POTENZA E ALTA
More informationState of the ART: HIV Cure where are we now and. where are we going? Jintanat Ananworanich, MD, PhD MHRP
State of the ART: HIV Cure where are we now and ì where are we going? Jintanat Ananworanich, MD, PhD Associate Director for Therapeu1cs Research US Military HIV Research Program (MHRP) Maryland, USA Deputy
More informationHIV Basics: Pathogenesis
HIV Basics: Pathogenesis Michael Saag, MD, FIDSA University of Alabama, Birmingham Director, Center for AIDS Research ACTHIV 2011: A State-of-the-Science Conference for Frontline Health Professionals Learning
More informationDNA Genotyping in HIV Infection
Frontier AIDS Education and Training Center DNA Genotyping in HIV Infection Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS Clinical Program; Professor of Medicine, Division of Infectious
More informationAntiretroviral Therapy in Simian Immunodeficiency Virus-Infected Sooty Mangabeys: Implications for AIDS Pathogenesis
Antiretroviral Therapy in Simian Immunodeficiency Virus-Infected Sooty Mangabeys: Implications for AIDS Pathogenesis Francesca Calascibetta, Emory University Luca Micci, Emory University Diane Carnathan,
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationIAS 2013 Towards an HIV Cure Symposium
Entinostat is a histone deacetylase (HDAC) inhibitor selective for class 1 HDACs and activates HIV production from latently infected primary T-cells Fiona Wightman Monash University, Melbourne, Australia
More informationCD4 Depletion in SIV-Infected Macaques Results in Macrophage and Microglia Infection with Rapid Turnover of Infected Cells
CD4 Depletion in SIV-Infected Macaques Results in Macrophage and Microglia Infection with Rapid Turnover of Infected Cells Luca Micci, Emory University Xavier Alvarez, Tulane University Robin I. Iriele,
More informationPreventive and therapeutic HIV vaccines. Markus Bickel Infektiologikum Frankfurt
Preventive and therapeutic HIV vaccines Markus Bickel Infektiologikum Frankfurt No conflicts to declare Disclosures Background FAQ: by patients and colleagues Publication about promising results, especially
More informationLoss of CD96 Expression as a New Biomarker for T-cell Senescence in HIV-1 Infection
Loss of CD96 Expression as a New Biomarker for T-cell Senescence in HIV-1 Infection Mohamed El-Far, PhD CHUM research center (CRCHUM) University of Montreal, QC Canada 6th International Workshop on HIV
More informationImaging B Cell Follicles to Investigate HIV/SIV Persistence. Elizabeth Connick, M.D. University of Arizona May 8, 2017
Imaging B Cell ollicles to Investigate HIV/SIV Persistence Elizabeth Connick, M.D. University of Arizona May 8, 2017 Most HIV Replication Occurs In Secondary Lymphoid Tissues Tenner-Racz K et al. Am J
More informationHIV Disease Pathogenesis
Slide Presentation HIV Disease Pathogenesis Bethesda, MD What Do We Mean by Pathogenesis Today? 1 Survival from Age 25 Years (N = 3,990) Probability of Survival 0.75 0.5 0.25 0 25 30 35 40 45 50 55 60
More informationLow-Level Viremia in HIV
Mountain West AIDS Education and Training Center Low-Level Viremia in HIV Brian R. Wood, MD Medical Director, Mountain West AETC ECHO Telehealth Program Assistant Professor of Medicine, University of Washington
More informationAlexander O. Pasternak, Mirte Scherpenisse, Ben Berkhout
Cell-associated HIV-1 unspliced to multiply spliced RNA ratio at 12 weeks ART correlates with markers of immune activation and apoptosis and predicts the CD4 + T-cell count at 96 weeks ART Alexander O.
More information2015 Towards an HIV Cure Symposium 18 & 19 July 2015 Hyatt Regency Hotel, Vancouver, Canada
2015 Towards an HIV Cure Symposium 18 & 19 July 2015 Hyatt Regency Hotel, Vancouver, Canada Saturday 18 th July 08h30 09h00 09h00 09h20 09h20 9h50 9h50 10h05 Opening Keynote Community Registration Welcome
More information0% 0% 0% Parasite. 2. RNA-virus. RNA-virus
HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which
More informationEngineered Immune-Mobilising Monoclonal T Cell Receptors for HIV Cure
Engineered Immune-Mobilising Monoclonal T Cell Receptors for HIV Cure Zoë Wallace Nuffield Dept. of Medicine University of Oxford 23 rd Annual Conference of the British HIV Association The HIV Reservoir
More informationKimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,
More informationClinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents
Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents 1 Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in
More informationThe HIV Cure Agenda. CHIVA Oct Nigel Klein. Institute of Child Health and Great Ormond Street Hospital, London, UK
The HIV Cure Agenda CHIVA Oct 2016 Nigel Klein Institute of Child Health and Great Ormond Street Hospital, London, UK 2 How frequently is HIV cured? The Berlin patient Restriction of HIV entry CD4 is
More informationModels of HIV during antiretroviral treatment
Models of HIV during antiretroviral treatment Christina M.R. Kitchen 1, Satish Pillai 2, Daniel Kuritzkes 3, Jin Ling 3, Rebecca Hoh 2, Marc Suchard 1, Steven Deeks 2 1 UCLA, 2 UCSF, 3 Brigham & Womes
More informationRapid Seeding of the Viral Reservoir Prior to SIV Viremia in Rhesus Monkeys
Rapid Seeding of the Viral Reservoir Prior to SIV Viremia in Rhesus Monkeys The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.
More informationMDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007
MDR HIV and Total Therapeutic Failure Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 Objectives Case study Definitions Fitness Pathogenesis of resistant virus
More informationID Week 2016: HIV Update
Mountain West AIDS Education and Training Center ID Week 2016: HIV Update Robert Harrington, M.D. This presentation is intended for educational use only, and does not in any way constitute medical consultation
More informationBeyond HAART: Outline. HIV-1 Time Line. Outline. Approaches to HIV Eradication 8/15/2013
8/5/203 Beyond HAART: Approaches to HIV Eradication I have no financial conflicts of interest to disclose 8 August 203 Adam Spivak MD Visiting Instructor, Division of Infectious Diseases University of
More informationDr Alan Winston. Imperial College Healthcare NHS Trust London. 7-8 October 2010, Queen Elizabeth II Conference Centre, London.
BHIVA AUTUMN CONFERENCE 2010 Including CHIVA Parallel Sessions Dr Alan Winston Imperial College Healthcare NHS Trust London 7-8 October 2010, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationScottish Medicines Consortium
Scottish Medicines Consortium raltegravir, 400mg film-coated tablet (Isentress) No. (461/08) Merck, Sharp and Dohme Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment
More informationInvited Review CROI 2018: Advances in Basic Science Understanding of HIV
Invited Review CROI 2018: Advances in Basic Science Understanding of HIV Mario Stevenson, PhD The conference on Retroviruses and Opportunistic Infections represents the most important venue for the dissemination
More informationPathogenesis Update Robert F. Siliciano, MD, PhD
Pathogenesis Update Robert F. Siliciano, MD, PhD Professor of Medicine and Molecular Biology and Genetics Johns Hopkins University School of Medicine Investigator, Howard Hughes Medical Institute HIV-1
More informationAlternate Antibody-Based Therapeutic Strategies To Purge the HIV Cell Reservoir
Alternate Antibody-Based Therapeutic Strategies To Purge the HIV Cell Reservoir Giuseppe Pantaleo, M.D. Professor of Medicine Head, Division of Immunology and Allergy Executive Director, Swiss Vaccine
More informationHIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD. Professor of Medicine University of California, San Diego
HIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD Professor of Medicine University of California, San Diego Disclosures Grant/research support Abbvie Gilead Sciences
More informationVirological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo
Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline
More informationInconsistent HIV reservoir dynamics and immune responses following anti-pd-1 therapy
Letter to Editor (Annals of Oncology): Inconsistent HIV reservoir dynamics and immune responses following anti-pd-1 therapy in cancer patients with HIV infection E. P. Scully 1,2,3, R. L. Rutishauser 4,
More informationTarget Cell Availability, Rather than Breast Milk Factors, Dictates Mother-to-Infant Transmission of SIV in Sooty Mangabeys and Rhesus Macaques
Target Cell Availability, Rather than Breast Milk Factors, Dictates Mother-to-Infant Transmission of SIV in Sooty Mangabeys and Rhesus Macaques Ann Chahroudi, Emory University Emily Cartwright, Emory University
More informationNature Medicine: doi: /nm.4411
Supplementary Figure 1. Plasma viral load decay characteristics in each of 4 monkey cohorts studied after prolonged ART. A. Decay in 5 SIV infected animals treated ART for 20-22 weeks. B, C. Decay in additional
More informationChanges in cellular HIV DNA levels during the MONET trial: 144 Weeks of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs
Changes in cellular HIV DNA levels during the MONET trial: 144 Weeks of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs Anna Maria Geretti, Jose R Arribas, Johan Vingerhoets, Geraldine Foster, Sabine
More informationHIV remission after discontinuing ART: is it achievable?
HIV remission after discontinuing ART: is it achievable? Jintanat Ananworanich, MD, PhD Associate Director for Therapeutics Research US Military HIV Research Program Maryland, USA jananworanich@hivresearch.org
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationAvailability of activated CD4+ T cells dictates the level of viremia in naturally SIV-infected sooty mangabeys
Availability of activated CD4+ T cells dictates the level of viremia in naturally SIV-infected sooty mangabeys Nichole R. Klatt, Emory University Francois Villinger, Emory University Pavel Bostik, Emory
More informationProfessor Anna Maria Geretti
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor Anna Maria Geretti Institute of Infection & Global Health, University of Liverpool 1-4 April 2014, Arena and Convention Centre Liverpool THIRD JOINT
More informationFunctional and transcriptional properties of DC distinguish a subset of HIV-1 controller neutralizers G E S I D A
Functional and transcriptional properties of DC distinguish a subset of HIV-1 controller neutralizers Enrique Martin-Gayo Ph.D Ragon Institute of MGH, MIT and Harvard Laboratory Dr. Xu G. Yu Mo B CD4 DC
More informationTB Intensive Tyler, Texas December 2-4, Tuberculosis and HIV Co-Infection. Lisa Y. Armitige, MD, PhD. December 4, 2008.
TB Intensive Tyler, Texas December 2-4, 2008 Tuberculosis and HIV Co-Infection Lisa Y. Armitige, MD, Ph.D. December 4, 2008 Tuberculosis and HIV Co Infection Lisa Y. Armitige, MD, PhD Assistant Professor
More informationDeterminants of residual viraemia during combination HIV treatment: Impacts of baseline HIV RNA levels and treatment choice
DOI: 10.1111/hiv.12323 ORIGINAL RESEARCH Determinants of residual viraemia during combination HIV treatment: Impacts of baseline HIV RNA levels and treatment choice E McKinnon, 1, * A Castley, 2,3, * L
More informationCROI 2014: Conference On Retroviruses And Opportunistic Infections
CROI 2014: Conference On Retroviruses nd Opportunistic Infections TUESY, MRCH 4 Investigator Time Session Location Title Oral Poster Other uthors Rosenberg, Eli 0-3 Prevention and Epidemiology: Evolving
More information